Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2015 | 1 |
2017 | 2 |
2018 | 1 |
2019 | 1 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for
xinan qin
Your search for
Xinnan Qin
retrieved no results
Rifampicin synergizes the toxicity of insecticides against the green peach aphid, Myzus persicae.
Ecotoxicol Environ Saf. 2024 May;276:116291. doi: 10.1016/j.ecoenv.2024.116291. Epub 2024 Apr 5.
Ecotoxicol Environ Saf. 2024.
PMID: 38581910
Free article.
Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.
Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J.
Wu H, et al.
Oncotarget. 2017 Apr 29;8(33):54364-54377. doi: 10.18632/oncotarget.17532. eCollection 2017 Aug 15.
Oncotarget. 2017.
PMID: 28903348
Free PMC article.
Item in Clipboard
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL, Zhou C, Lu S, Qin S, Pan H, Wu G, Cheng Y, Liu X, Han B, Zhu Y, Zhong Z, Huang C, Chen L, Liang H, Li E, Jiang G.
Wu YL, et al.
Lung Cancer. 2019 Apr;130:18-24. doi: 10.1016/j.lungcan.2019.01.016. Epub 2019 Jan 31.
Lung Cancer. 2019.
PMID: 30885342
Clinical Trial.
Item in Clipboard
In vivo monitoring of magnetically labeled mesenchymal stem cells homing to rabbit hepatic VX2 tumors using magnetic resonance imaging.
Qin Y, Zhuo L, Cai J, He X, Liu B, Feng C, Zhang L.
Qin Y, et al.
Mol Med Rep. 2018 Jan;17(1):452-458. doi: 10.3892/mmr.2017.7902. Epub 2017 Oct 26.
Mol Med Rep. 2018.
PMID: 29115453
Item in Clipboard
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer.
Sun Y, Wang JW, Liu YY, Yu QT, Zhang YP, Li K, Xu LY, Luo SX, Qin FZ, Chen ZT, Liu WC, Zhou QH, Chen Q, Nan KJ, Liu XQ, Liu W, Liang HJ, Lu HS, Wang XW, Wang JJ, Song SP, Tu YR, Zhou JM, Li WL, Yao C; Endostar Phase III NSCLC Study Group.
Sun Y, et al.
Thorac Cancer. 2013 Nov;4(4):440-448. doi: 10.1111/1759-7714.12050.
Thorac Cancer. 2013.
PMID: 28920215
Free article.
Item in Clipboard
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y.
Wu YL, et al.
Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.
Ann Oncol. 2015.
PMID: 26105600
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite